{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:54:42Z","timestamp":1773838482109,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T00:00:00Z","timestamp":1384819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11096-013-9876-7","type":"journal-article","created":{"date-parts":[[2013,11,17]],"date-time":"2013-11-17T21:42:28Z","timestamp":1384724548000},"page":"172-181","source":"Crossref","is-referenced-by-count":19,"title":["Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan"],"prefix":"10.1007","volume":"36","author":[{"given":"Teng-Chou","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaw-Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Sung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"key":"9876_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cncr.11520","volume":"98","author":"G Garcia-Manero","year":"2003","unstructured":"Garcia-Manero G, Faderl S, O\u2019Brien S, et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437\u201357.","journal-title":"Cancer"},{"key":"9876_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","volume":"131","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207\u201319.","journal-title":"Ann Intern Med"},{"key":"9876_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00001622-200101000-00002","volume":"13","author":"MJ Mauro","year":"2001","unstructured":"Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3\u20137.","journal-title":"Curr Opin Oncol"},{"key":"9876_CR4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp070482","volume":"64","author":"C Fausel","year":"2007","unstructured":"Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm. 2007;64:S9\u201315.","journal-title":"Am J Health Syst Pharm"},{"key":"9876_CR5","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530\u20139.","journal-title":"Blood"},{"key":"9876_CR6","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","journal-title":"Blood"},{"key":"9876_CR7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","volume":"7","author":"S O\u2019Brien","year":"2009","unstructured":"O\u2019Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Cancer Netw. 2009;7:984\u20131023.","journal-title":"J Natl Compr Cancer Netw"},{"key":"9876_CR8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"9876_CR9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejon.2011.10.002","volume":"16","author":"L Wood","year":"2012","unstructured":"Wood L. A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs. 2012;16:432\u20138.","journal-title":"Eur J Oncol Nurs"},{"key":"9876_CR10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481\u201396.","journal-title":"Pharmacoeconomics"},{"key":"9876_CR11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"9876_CR12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.leukres.2012.01.021","volume":"36","author":"A Gater","year":"2012","unstructured":"Gater A, Heron L, Abetz-Webb L, et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36:817\u201325.","journal-title":"Leuk Res"},{"key":"9876_CR13","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401\u201311.","journal-title":"Blood"},{"key":"9876_CR14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-12-359","volume":"12","author":"CS Chang","year":"2012","unstructured":"Chang CS, Yang YH, Hsu CN, Lin MT. Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. BMC Health Serv Res. 2012;12:359.","journal-title":"BMC Health Serv Res"},{"key":"9876_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"issue":"IV","key":"9876_CR16","first-page":"26","volume":"40","author":"CN Klabunde","year":"2002","unstructured":"Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40(IV):26\u201335.","journal-title":"Med Care"},{"key":"9876_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","volume":"26","author":"EQ Wu","year":"2010","unstructured":"Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61\u20139.","journal-title":"Curr Med Res Opin"},{"key":"9876_CR18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1547-5069.2003.tb00001.x","volume":"35","author":"PV Burkhart","year":"2003","unstructured":"Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35:207.","journal-title":"J Nurs Scholarsh"},{"key":"9876_CR19","first-page":"CD000011","volume":"2","author":"RB Haynes","year":"2008","unstructured":"Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.","journal-title":"Cochrane Database Syst Rev"},{"key":"9876_CR20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pec.2007.08.011","volume":"69","author":"AC Mardby","year":"2007","unstructured":"Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns. 2007;69:158\u201364.","journal-title":"Patient Educ Couns"},{"key":"9876_CR21","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935\u201342.","journal-title":"Clin Cancer Res"},{"key":"9876_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1345\/aph.1D252","volume":"38","author":"SA Vik","year":"2004","unstructured":"Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother. 2004;38:303\u201312.","journal-title":"Ann Pharmacother"},{"key":"9876_CR23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","volume":"94","author":"AH Partridge","year":"2002","unstructured":"Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"9876_CR24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35:626\u201330.","journal-title":"Leuk Res"},{"key":"9876_CR25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archinte.1990.00390190143023","volume":"150","author":"JA Cramer","year":"1990","unstructured":"Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509\u201310.","journal-title":"Arch Intern Med"},{"key":"9876_CR26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397.","journal-title":"N Engl J Med"},{"key":"9876_CR27","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International randomized study of interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"9876_CR28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835\u201340.","journal-title":"Blood"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9876-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-013-9876-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9876-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T11:11:45Z","timestamp":1647083505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-013-9876-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["9876"],"URL":"https:\/\/doi.org\/10.1007\/s11096-013-9876-7","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]}}}